ArticleTrends in cancer2022
Diversifying preclinical research tools: expanding patient-derived models to address cancer health disparities.
Article in Trends in cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Preclinical research (on rare diseases): we need to talk about health equity.Mammalian genome : official journal of the International Mammalian Genome Society · 2025Review
- The role of multi-organ cancer predisposition genes in the risk of inherited and histologically diverse gastric cancer.EBioMedicine · 2025Article
- Creation and Characterization of a Breast Cancer Tissue Microarray Including Black and White Patients from Florida and Hispanic Patients from Puerto Rico and Florida.Cancer research communications · 2025Article
- An Overview of In Vitro Models of Alcohol-Related Hepatocellular Carcinoma.Cancer medicine · 2025Review
- Development and Application of Genetic Ancestry Reconstruction Methods to Study Diversity of Patient-Derived Models in the NCI PDXNet Consortium.Cancer research communications · 2024Article
- Patient-Derived-Xenografts in Mice: A Preclinical Platform for Cancer Research.Cold Spring Harbor perspectives in medicine · 2024Review
- Advancing gastric cancer precision medicine with novel genomic screensThe Journal of pathology · 2023Article
- DEIA is essential to advance the goals of translational science: Perspectives from NCATS.Journal of clinical and translational science · 2023Article
- Multiregional Sequencing Analysis Reveals Extensive Genetic Heterogeneity in Gastric Tumors from Latinos.Cancer research communications · 2022Article
- In Vitro Cancer Models: A Closer Look at Limitations on Translation.Bioengineering (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cancer health disparities define a critical healthcare issue for racial/ethnic minorities in the USA. Key findings have led to cancer treatment improvements tailored to minority patients, but such successes have been rare. Here, we highlight how the use of patient-derived xenograft (PDX) and organoid models could resolve current blocks toward precision cancer health equity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.